^
Association details:
| Biomarker: | ABL1 G250E + ABL1 D276G + ABL1 T315I |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
th blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports
Published date:
03/25/2021
Excerpt:
A 69-year-old Japanese male with R/R Ph+ ALL was treated with conventional chemotherapy and dasatinib in April 2016...However, he developed a second relapse after the emergence of triple compound mutations (G250E/D276G/T315I) in November 2018. He subsequently received a total of nine cycles of BLIN and ponatinib combination therapy, which resulted in sustained mCR without any adverse event....BLIN + ponatinib combination therapy was highly effective for R/R Ph+ ALL without any incidence of severe adverse events.
DOI:
10.1186/s13256-021-02771-z
